Monoclonal antibody combination

This page covers all Monoclonal antibody combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting IL-2 receptor alpha (CD25) and TNF-alpha, SARS-CoV-2 spike protein receptor-binding domain, CD20 (ofatumumab) and CD38 (daratumumab).

Targets

IL-2 receptor alpha (CD25) and TNF-alpha · SARS-CoV-2 spike protein receptor-binding domain · CD20 (ofatumumab) and CD38 (daratumumab)

Marketed (1)

• daclizumab, infliximab · University of Iowa · Immunology
  This is a combination of two monoclonal antibodies: daclizumab blocks IL-2 receptor alpha on T cells to reduce immune activation, while infliximab blocks TNF-alpha to suppress inflammatory cytokine signaling.

Phase 3 pipeline (3)

• BRII-196/BRII-198 · National Institute of Allergy and Infectious Diseases (NIAID) · Infectious Disease / Virology
  BRII-196/BRII-198 is a combination of two monoclonal antibodies that neutralize SARS-CoV-2 spike protein to prevent and treat COVID-19 infection.
• Ofatumumab combined with daratumumab · The First People's Hospital of Changzhou · Oncology
  Ofatumumab and daratumumab are monoclonal antibodies that work synergistically to target and eliminate malignant B cells and plasma cells by binding to CD20 and CD38 respectively, triggering immune-mediated cell death.
• AZD7442 · AstraZeneca · Infectious Disease / Virology
  AZD7442 is a combination of two monoclonal antibodies that bind to the SARS-CoV-2 spike protein to neutralize the virus and provide passive immunity.